Anti-EGFR Antibody Reduces Lung Nodules by Inhibition of EGFR-Pathway in a Model of Lymphangioleiomyomatosis

Figure 4

LAM/TSC cell administration causes enlargement of the airspaces that reverted by anti-EGFR Ab and rapamycin treatment. (a) LAM/TSC cells cause progressive lung degeneration. Lungs of nude mice 15, 30, and 60 weeks after LAM/TSC cell administration (lower panels) are stained with hematoxylin and eosin and compared to control of the same age (upper panels). Scale bars: 200 μm. (b) The (ae/lu) (fraction of air exchanging parenchyma relative to lung parenchyma) is shown as the mean of ±SEM of 10 animals per group, expressed as a percentage. versus (ae/lu) in control; ^## versus (ae/lu) in mouse lungs 15 weeks after LAM/TSC cell administration; versus (ae/lu) in mouse lungs 30 weeks after LAM/TSC cells administration. (c) Anti-EGFR Ab reduces the enlargement of airspaces caused by LAM/TSC cell administration such as rapamycin that induced a thickening of the parenchyma. Scale bars: 200 μm. (d) The (ae/lu) relative to control mice, 30-week LAM/TSC cell-administered mice, mice treated with anti-EGFR Ab or rapamycin is shown as the mean of ±SEM of 10 animals per group, expressed as percentage. , (ae/lu) in lungs of cell-administered mice versus (ae/lu) in lungs of control mice. ^###   (ae/lu) in lungs of drug-treated mice after cell administration versus lungs of cell-administered mice.

(a)

(b)

(c)

(d)